Companies: 49,246 Total Market Cap: 132591774254860.43

Ascendis Pharma A/S

NASDAQ: ASND

Healthcare Biotechnology

Rank #1932

Market Cap 9.68 B

Volume 443,064

Price 160.33

Change (%) 1.73%

Country or region

Denmark

Ascendis Pharma A/S's latest marketcap:

9.68 B

As of 05/20/2025, Ascendis Pharma A/S's market capitalization has reached $9.68 B. According to our data, Ascendis Pharma A/S is the 1932th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap	9.68 B
Revenue (ttm)	398.51 M
Net Income (ttm)	-369,298,530
Shares Out	60.37 M
EPS (ttm)	-6.29
Forward PE	0.00
Ex-Dividend Date	n/a
Earnings Date	05/01/2025

Market Cap Chart

Data Updated: 05/20/2025

Ascendis Pharma A/S's yearly market capitalization.

Ascendis Pharma A/S has seen its market value grow from $460.30 M to $9.68 B since 2015, representing a total increase of 2,002.91% and an annual compound growth rate (CAGR) of 38.33%.

Date	Market Cap	Change (%)
05/20/2025	$9.68 B	15.89%
12/31/2024	$7.92 B	9.08%
12/29/2023	$7.26 B	4.27%
12/30/2022	$6.96 B	-3.83%
12/31/2021	$7.24 B	-17.63%
12/31/2020	$8.79 B	32.38%
12/31/2019	$6.64 B	152.21%
12/31/2018	$2.63 B	80.76%
12/29/2017	$1.46 B	185.54%
12/30/2016	$510.20 M	10.84%
12/31/2015	$460.30 M

Company Profile

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company dedicated to developing innovative therapies using its proprietary TransCon technology. The company operates globally, with a focus on addressing unmet medical needs in Denmark, Europe, North America, and other international markets.

Key Products

SKYTROFA – A treatment for pediatric patients with growth hormone deficiency.
YORVIPATH – A once-daily subcutaneous injection designed for adults with chronic hypoparathyroidism.

Pipeline & Research Focus

The company is actively advancing its pipeline, which includes:

Three independent endocrinology rare disease product candidates in clinical development.
Oncology therapeutic candidates in various stages of research.

Company Background

Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Frequently Asked Questions

As of 05/20/2025, Ascendis Pharma A/S (including the parent company, if applicable) has an estimated market capitalization of $9.68 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Ascendis Pharma A/S global market capitalization ranking is approximately 1932 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region	Denmark
Founded	2006
IPO Date	01/28/2015
Employees	1,017
CEO	Jan Mikkelsen
Sector	Healthcare
Industry	Biotechnology
Address	Tuborg Boulevard 12 Hellerup, 2900 Denmark
Website	https://ascendispharma.com